News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
483,499 Results
Type
Article (8017)
Company Profile (139)
Press Release (475247)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166761)
Career Advice (305)
Deals (25740)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9761)
Job Trends (8575)
News (238245)
Policy (17923)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33161)
ALS (102)
Alzheimer's disease (970)
Antibody-drug conjugate (ADC) (258)
Approvals (10350)
Artificial intelligence (313)
ASCO (159)
Autoimmune disease (201)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (104)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (135)
Brain cancer (28)
Breast cancer (503)
Cancer (3589)
Cardiovascular disease (214)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (473)
Cervical cancer (34)
Clinical research (47777)
Collaboration (1215)
Commercialization (2)
Compensation (1397)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (720)
Cystic fibrosis (84)
Data (5546)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (337)
Diagnostics (4161)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (149)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (160)
Earnings (73135)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87508)
Executive appointments (686)
FDA (12316)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (898)
Gene editing (125)
Generative AI (9)
Gene therapy (310)
GLP-1 (286)
Government (950)
Grass and pollen (2)
Guidances (280)
Healthcare (9319)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (61)
Immunology and inflammation (98)
Immuno-oncology (55)
Indications (153)
Infectious disease (940)
Inflammatory bowel disease (125)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (247)
Interviews (42)
IPO (12380)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (1)
Liver cancer (44)
Longevity (15)
Lung cancer (496)
Lymphoma (245)
Machine learning (27)
Management (3)
Manufacturing (516)
Marketing (7)
MASH (116)
Medical device (8643)
Medtech (8771)
Mergers & acquisitions (14362)
Metabolic disorders (693)
mRNA (50)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (214)
Neuropsychiatric disorders (38)
Neuroscience (1796)
NextGen: Class of 2026 (3153)
Non-profit (846)
Obesity (219)
Opinion (10)
Ovarian cancer (157)
Pain (170)
Pancreatic cancer (191)
Parkinson's disease (197)
Partnered (11)
Patents (459)
Patient recruitment (488)
Peanut (31)
People (41168)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15441)
Phase 2 (21334)
Phase 3 (14367)
Pipeline (6750)
Policy (18)
Postmarket research (1572)
Preclinical (6527)
Press Release (34)
Prostate cancer (187)
Psychedelics (7)
Radiopharmaceuticals (188)
Rare diseases (558)
Real estate (3021)
Recruiting (6)
Regulatory (14733)
Reports (16)
Research institute (580)
Resumes & cover letters (46)
Rett syndrome (39)
RNA editing (5)
RSV (47)
Schizophrenia (99)
Series A (151)
Series B (119)
Service/supplier (4)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (313)
Venture capital (17)
Weight loss (72)
Women's health (76)
Date
Today (84)
Last 7 days (339)
Last 30 days (1196)
Last 365 days (19144)
2026 (11040)
2025 (19252)
2024 (22985)
2023 (26541)
2022 (34587)
2021 (37167)
2020 (33479)
2019 (23257)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21683)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (227)
Alabama (72)
Alaska (2)
Arizona (294)
Arkansas (11)
Asia (17853)
Australia (2091)
California (11590)
Canada (3056)
China (507)
Colorado (467)
Connecticut (395)
Delaware (205)
Europe (24580)
Florida (1734)
Georgia (366)
Hawaii (3)
Idaho (46)
Illinois (682)
India (44)
Indiana (310)
Iowa (13)
Japan (390)
Kansas (99)
Kentucky (30)
Louisiana (25)
Maine (25)
Maryland (1159)
Massachusetts (7632)
Michigan (300)
Minnesota (546)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2560)
New Mexico (12)
New York (2750)
North Carolina (1238)
North Dakota (4)
Northern California (5779)
Ohio (269)
Oklahoma (14)
Oregon (15)
Pennsylvania (2204)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (75)
South Dakota (1)
Southern California (4806)
Tennessee (114)
Texas (1869)
United States (37740)
Utah (348)
Vermont (1)
Virginia (147)
Washington D.C. (38)
Washington State (901)
West Virginia (1)
Wisconsin (73)
483,499 Results for "gradalis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gradalis Appoints Steven D. Weinstein as Chief Executive Officer
January 12, 2026
·
4 min read
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
·
8 min read
Press Releases
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
March 17, 2025
·
8 min read
Lone Star Bio
Gradalis to Participate in the Cantor Global Healthcare Conference
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.
September 21, 2023
·
4 min read
Lone Star Bio
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.
November 16, 2023
·
9 min read
Lone Star Bio
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control.
January 4, 2024
·
7 min read
Press Releases
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
February 5, 2025
·
6 min read
Lone Star Bio
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
Gradalis, Inc. announced a peer-reviewed publication in Cancers, highlighting the newly discovered critical clinical role of clonal neoantigens in the durable efficacy of immunotherapies in oncology and the potential to use clonal neoantigens as a new biomarker to better identify patients who will best respond to certain immunotherapies.
December 5, 2023
·
12 min read
Lone Star Bio
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.
September 28, 2023
·
7 min read
Lone Star Bio
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.
March 29, 2023
·
3 min read
1 of 48,350
Next
